Nevertheless, the PD-L1 IHC test was recommended by the FDA as a tool for stratifying NSCLC patients before pembrolizumab therapy because of the strong correlation of tumor PD-L1 expression (over 50% cells expressing PD-L1) and higher response rate, as well as prolonged PFS and OS [32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.